{
  "outcomes_metadata": {
    "timestamp": "2025-09-08T18:21:49.501458",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "total_unique_outcomes": 28,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "FR",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        {
          "name": "Overall survival (OS)",
          "details": [
            "Median OS (e.g., 10.6–12.5 months for sotorasib, 11.3 months for docetaxel)",
            "Hazard ratio (HR) for OS (e.g., HR 1.01 [95% CI: 0.77, 1.33], p=0.53; indirect comparison HR=0.611 [95% CI: 0.451, 0.829])",
            "Kaplan-Meier 12-month OS rate (e.g., 45.96% sotorasib, 46.49% docetaxel)",
            "Defined as time from randomisation to death from any cause"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "DE",
              "source_type": "hta_submission"
            },
            {
              "country": "NL",
              "source_type": "clinical_guideline"
            },
            {
              "country": "EN",
              "source_type": "clinical_guideline"
            },
            {
              "country": "SE",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Event-free survival",
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Prolonged survival",
          "reported_by": [
            {
              "country": "SE",
              "source_type": "clinical_guideline"
            }
          ]
        }
      ],
      "response_measures": [
        {
          "name": "Objective response rate (ORR)",
          "details": [
            "Primary endpoint in several sources",
            "Measured by RECIST 1.1 criteria in some sources",
            "E.g., 28.1% [95% CI: 21.5, 35.4] sotorasib vs 13.2% [95% CI: 8.6, 19.2] docetaxel; p<0.001"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "NL",
              "source_type": "clinical_guideline"
            },
            {
              "country": "DK",
              "source_type": "clinical_guideline"
            },
            {
              "country": "EN",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Disease control rate (DCR)",
          "details": [
            "E.g., 83% for sotorasib vs docetaxel"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Duration of response (DoR)",
          "details": [
            "Median DoR reported"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "DK",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Response to immunotherapy monotherapy",
          "reported_by": [
            {
              "country": "DK",
              "source_type": "clinical_guideline"
            }
          ]
        }
      ],
      "progression_measures": [
        {
          "name": "Progression-free survival (PFS)",
          "details": [
            "Median PFS (e.g., 5.6–6.7 months for sotorasib)",
            "HR for PFS (e.g., HR 0.66, 95% CI: 0.51, 0.86, p=0.002)",
            "12-month PFS rates (e.g., 24.8% sotorasib vs 10.1% docetaxel)",
            "Defined as time from randomisation until disease progression or death from any cause, whichever occurred first, assessed by blinded independent central review"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "DE",
              "source_type": "hta_submission"
            },
            {
              "country": "NL",
              "source_type": "clinical_guideline"
            },
            {
              "country": "DK",
              "source_type": "clinical_guideline"
            },
            {
              "country": "EN",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Time to progression",
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Time to progression on subsequent therapy",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Time to next treatment",
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Duration of treatment",
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            }
          ]
        }
      ]
    },
    "safety": {
      "adverse_events": [
        {
          "name": "Adverse events (AEs)",
          "details": [
            "Measured by CTCAE v5.0 in some sources",
            "Includes total AEs, treatment-related AEs, specific AEs (diarrhoea, increased ALT/AST, fatigue, anaemia, constipation, neutropenia, fever, alopecia, stomatitis, peripheral oedema, peripheral neuropathy, blood and lymphatic system disorders, infections and infestations, liver disorders, interstitial lung disease, etc.)"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "DE",
              "source_type": "hta_submission"
            },
            {
              "country": "NL",
              "source_type": "clinical_guideline"
            },
            {
              "country": "DK",
              "source_type": "clinical_guideline"
            },
            {
              "country": "EN",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Dose modification-related adverse drug reactions (ADRs)",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Potential risk of serious side effects on the skin",
          "reported_by": [
            {
              "country": "FR",
              "source_type": "clinical_guideline"
            }
          ]
        }
      ],
      "serious_events": [
        {
          "name": "Serious adverse events (SAEs)",
          "details": [
            "Includes Grade 3–4 AEs, severe AEs, treatment-related AEs resulting in death"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "DE",
              "source_type": "hta_submission"
            },
            {
              "country": "DK",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Mortality-related toxicity",
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            }
          ]
        }
      ],
      "discontinuations": [
        {
          "name": "Discontinuation rate due to adverse events",
          "details": [
            "Includes treatment-related AEs leading to discontinuation"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "DE",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Treatment discontinuation due to AEs",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "DK",
              "source_type": "clinical_guideline"
            }
          ]
        }
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        {
          "name": "Quality of life (QoL)",
          "details": [
            "Overall health status/quality of life (stable in sotorasib group, deterioration in docetaxel group)",
            "Measured by EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D VAS, BPI-SF, FACT-G GP5, PGI-C",
            "Includes assessment of symptoms (pain, swelling, dyspnea, hair loss, chest bleeding, cough)",
            "Change in mean squared minimums from baseline to week 12 (e.g., 6.93 [95% CI: 3.66, 10.19])"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            },
            {
              "country": "DE",
              "source_type": "hta_submission"
            },
            {
              "country": "NL",
              "source_type": "clinical_guideline"
            },
            {
              "country": "EN",
              "source_type": "clinical_guideline"
            },
            {
              "country": "SE",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Health status",
          "details": [
            "Measured by EQ-5D VAS"
          ],
          "reported_by": [
            {
              "country": "DE",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Symptomatology and health status",
          "details": [
            "Assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C"
          ],
          "reported_by": [
            {
              "country": "DE",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Preservation of quality of life",
          "reported_by": [
            {
              "country": "SE",
              "source_type": "clinical_guideline"
            }
          ]
        }
      ],
      "functional_status": [
        {
          "name": "Time to deterioration of overall health status",
          "details": [
            "Delayed time to deterioration (e.g., HR 0.694)"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Time to deterioration of physical functioning",
          "details": [
            "Delayed time to deterioration (e.g., HR 0.95)"
          ],
          "reported_by": [
            {
              "country": "PT",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Time to deterioration in quality of life",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        }
      ],
      "symptom_measures": [
        {
          "name": "Symptom control",
          "reported_by": [
            {
              "country": "SE",
              "source_type": "clinical_guideline"
            }
          ]
        }
      ]
    },
    "economic": {
      "cost_effectiveness": [
        {
          "name": "Incremental cost-utility ratio (ICUR)",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        },
        {
          "name": "Cost-utility analysis (CUA)",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        }
      ],
      "utilities": [
        {
          "name": "Utilities (as part of cost-utility analysis)",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        }
      ],
      "resource_utilization": [
        {
          "name": "Budget impact analysis (public payer perspective)",
          "reported_by": [
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        }
      ]
    },
    "other": {
      "exploratory_endpoints": [
        {
          "name": "Treatment according to evidence-based recommendations",
          "reported_by": [
            {
              "country": "DE",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Use of targeted therapy (Sotorasib)",
          "reported_by": [
            {
              "country": "DE",
              "source_type": "clinical_guideline"
            }
          ]
        },
        {
          "name": "Consensus-based recommendation",
          "reported_by": [
            {
              "country": "DE",
              "source_type": "clinical_guideline"
            }
          ]
        }
      ],
      "biomarkers": [
        {
          "name": "Consideration of patient overall condition (Karnofsky or ECOG performance status)",
          "reported_by": [
            {
              "country": "DE",
              "source_type": "clinical_guideline"
            },
            {
              "country": "PO",
              "source_type": "hta_submission"
            }
          ]
        }
      ]
    }
  }
}